Inhibition of tumor-associated CA9 is useful in the management of hypoxic tumors that do not respond to classic chemotherapy or radiotherapy, and many types of highly effective CA9 inhibitors have been developed and evaluated in vitro (16). This evidence concerns the gene CA9 and neoplasm.